Jakob D. Rudzki

Innsbruck, AT 
Innsbruck, AT 

Overview

Jakob Rudzki practices practicing medicine in Innsbruck, Austria.

His clinical expertise encompasses B-Cell Lymphoma, Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia (ALL), Burkitt Lymphoma, and Bone Marrow Transplant.

He is actively involved in clinical research, co-authoring 15 peer reviewed articles and participating in 2 clinical trials.

Gender

Male

Locations

Innsbruck, Austria
Other Locations
Oberwart, Austria

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA-7)
A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA-7)
Enrollment Status: Completed
Publish Date: December 01, 2025
Intervention Type: Biological, Drug
Study Drugs: Axicabtagene Ciloleucel, Platinum-containing salvage chemotherapy (eg, R-ICE) followed by high dose therapy (eg, BEAM) and autologous stem cell transplant in responders, Cyclophosphamide, Fludarabine
Study Phase: Phase 3
Pattern of Use and Safety/Effectiveness of Nivolumab in Routine Oncology Practice
Pattern of Use and Safety/Effectiveness of Nivolumab in Routine Oncology Practice
Enrollment Status: Completed
Publish Date: June 03, 2024
View 1 Less Clinical Trial

15 Total Publications

Austrian Real-world Experience With Standard of Care Brexucabtagene Autoleucel in Patients With Relapsed or Refractory Mantle-Cell Lymphoma.
Austrian Real-world Experience With Standard of Care Brexucabtagene Autoleucel in Patients With Relapsed or Refractory Mantle-Cell Lymphoma.
Journal: Transplantation and cellular therapy
Published: August 26, 2025

Frequently Asked Questions about Jakob D. Rudzki

Is Jakob D. Rudzki a top-rated expert for B-Cell Lymphoma?

MediFind is an objective health platform that identifies experts based on real-world data. Jakob D. Rudzki is classified as an Experienced expert for B-Cell Lymphoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Jakob D. Rudzki participate in research or clinical trials?

Yes. Jakob D. Rudzki has published 15 articles and abstracts on conditions like B-Cell Lymphoma. You can view a list of Jakob D. Rudzki's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Rudzki's expertise for a condition
ConditionClose
        View All 10 Experienced Conditions
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile